PDS Biotechnology (NASDAQ:PDSB - Get Free Report)'s stock had its "buy" rating reissued by equities research analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $21.00 price target on the stock.
A number of other equities research analysts have also issued reports on PDSB. StockNews.com lowered PDS Biotechnology from a "hold" rating to a "sell" rating in a research note on Saturday, November 9th. B. Riley reduced their price target on shares of PDS Biotechnology from $9.00 to $7.00 and set a "buy" rating on the stock in a report on Monday, November 25th. Finally, Alliance Global Partners upgraded PDS Biotechnology to a "strong-buy" rating in a report on Wednesday, August 21st. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, PDS Biotechnology has a consensus rating of "Moderate Buy" and an average price target of $11.67.
Get Our Latest Report on PDS Biotechnology
PDS Biotechnology Stock Performance
Shares of PDSB stock traded down $0.16 on Wednesday, reaching $1.81. The stock had a trading volume of 354,737 shares, compared to its average volume of 597,502. The stock has a market cap of $67.52 million, a P/E ratio of -1.56 and a beta of 1.85. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.84 and a current ratio of 2.84. PDS Biotechnology has a 1 year low of $1.53 and a 1 year high of $6.68. The company has a 50 day simple moving average of $2.64 and a 200 day simple moving average of $3.04.
Hedge Funds Weigh In On PDS Biotechnology
Large investors have recently modified their holdings of the stock. Tempus Wealth Planning LLC purchased a new stake in PDS Biotechnology in the second quarter worth $55,000. Ground Swell Capital LLC purchased a new stake in PDS Biotechnology in the 2nd quarter valued at about $67,000. Point72 Asia Singapore Pte. Ltd. bought a new position in PDS Biotechnology in the 2nd quarter worth about $115,000. Squarepoint Ops LLC purchased a new position in shares of PDS Biotechnology during the second quarter worth approximately $120,000. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of PDS Biotechnology during the second quarter valued at approximately $146,000. Institutional investors own 26.84% of the company's stock.
About PDS Biotechnology
(
Get Free Report)
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.
See Also
Before you consider PDS Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PDS Biotechnology wasn't on the list.
While PDS Biotechnology currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
